Seaport Therapeutics reported financial results for the quarter ended June 30, 2026, posting a net loss of $62.6 million compared to $15.1 million in the prior year period. The increase was driven by one-time non-cash stock-based compensation costs related to its May IPO and additional equity grants. Research and development expenses rose to $24.6 million from $13.4 million, while general and administrative expenses surged to $41.2 million from $5.1 million due to the same IPO-related charges. The company ended the quarter with $427.3 million in cash, cash equivalents, and investments, sufficient to fund operations into 2029. Clinically, Seaport highlighted positive Phase 1 proof-of-concept data for GlyphAgo, prompting plans to initiate Phase 2a trials in generalized anxiety disorder in the second half of 2026. Enrollment remains on track for the Phase 2b BUOY-1 trial of GlyphAllo in major depressive disorder, with topline data expected in the first half of 2027. Seaport Therapeutics is a clinical-stage therapeutics company developing novel neuropsychiatric medicines using its proprietary Glyph platform.

Seaport Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026, via a press release furnished as Exhibit 99.1. The filing is a routine-style 8-K for the following period.